# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-26-137930
**Filing Date:** 2026-4
**Character Count:** 9720
**Document Hash:** 4a5e7d93d903bf9bcb9da260e3be6de2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-137930.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001193125-26-137930

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 63

**CONFORMED PERIOD OF REPORT**: 20260401

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 26828443

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** April 01, 2026<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
On April 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Corporate Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | April 1, 2026 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

------

![Slide 4](catx-ex99_1s4.jpg)

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

------

![Slide 5](catx-ex99_1s5.jpg)

Proprietary Radioligand Platform Optimizes Therapeutic Index

------

![Slide 6](catx-ex99_1s6.jpg)

Proprietary Pb-Based Chelator Designed for Broader and Safer Use

------

![Slide 7](catx-ex99_1s7.jpg)

Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

------

![Slide 8](catx-ex99_1s8.jpg)

Imaging Optimizes Targeted Delivery to Tumor

------

![Slide 9](catx-ex99_1s9.jpg)

------

![Slide 10](catx-ex99_1s10.jpg)

Solid Tumors are an Attractive Market for Radiopharmaceuticals

------

![Slide 11](catx-ex99_1s11.jpg)

End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

------

![Slide 12](catx-ex99_1s12.jpg)

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

------

![Slide 13](catx-ex99_1s13.jpg)

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

------

![Slide 14](catx-ex99_1s14.jpg)

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

------

![Slide 15](catx-ex99_1s15.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 16](catx-ex99_1s16.jpg)

Compelling Anti-tumor Activity with Sustained or Deepening Responses

------

![Slide 17](catx-ex99_1s17.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 18](catx-ex99_1s18.jpg)

Best-in-class Safety Profile1

------

![Slide 19](catx-ex99_1s19.jpg)

VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level

------

![Slide 20](catx-ex99_1s20.jpg)

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

------

![Slide 21](catx-ex99_1s21.jpg)

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

------

![Slide 22](catx-ex99_1s22.jpg)

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

------

![Slide 23](catx-ex99_1s23.jpg)

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

------

![Slide 24](catx-ex99_1s24.jpg)

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

------

![Slide 25](catx-ex99_1s25.jpg)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

------

![Slide 26](catx-ex99_1s26.jpg)

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

------

![Slide 27](catx-ex99_1s27.jpg)

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

------

![Slide 28](catx-ex99_1s28.jpg)

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

------

![Slide 29](catx-ex99_1s29.jpg)

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

------

![Slide 30](catx-ex99_1s30.jpg)

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

------

![Slide 31](catx-ex99_1s31.jpg)

------

![Slide 32](catx-ex99_1s32.jpg)

Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026

------

![Slide 33](catx-ex99_1s33.jpg)

------

![Slide 34](catx-ex99_1s34.jpg)

Abbreviations

------

![Slide 35](catx-ex99_1s35.jpg)

APPENDIX

------

![Slide 36](catx-ex99_1s36.jpg)

------

![Slide 37](catx-ex99_1s37.jpg)

NETs Trials

------

![Slide 38](catx-ex99_1s38.jpg)

VMT-⍺-NET: Baseline Patient Characteristics in ASCO-GI 2026 Data Analysis

------

![Slide 39](catx-ex99_1s39.jpg)

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO-GI 2026 Data Analysis

------

![Slide 40](catx-ex99_1s40.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 41](catx-ex99_1s41.jpg)

VMT-⍺-NET: Signal of Sustained Anti-tumor Activity

------

![Slide 42](catx-ex99_1s42.jpg)

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

------

![Slide 43](catx-ex99_1s43.jpg)

Blood Creatinine During Follow-up for All Patients Treated (n=56)

------

![Slide 44](catx-ex99_1s44.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 45](catx-ex99_1s45.jpg)

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

------

![Slide 46](catx-ex99_1s46.jpg)

------

![Slide 47](catx-ex99_1s47.jpg)

Daily production at regional sites ensures supply of ready-to-administer product

------

![Slide 48](catx-ex99_1s48.jpg)

------

![Slide 49](catx-ex99_1s49.jpg)

Perspective's proprietary chelator has been optimized for lead-based RPTs

------

![Slide 50](catx-ex99_1s50.jpg)

Construct designed for better clinical outcome

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)

------

![Slide 53](catx-ex99_1s53.jpg)